Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended): A compound of the formulae:



or

wherein:

R_1 is ~~selected from H, halogen, $-CF_3$, $-OH$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, CN, $-CF_3$, or $-OH$;~~

~~or a moiety of the formulae:~~





~~or~~ ;

R_6 is ~~selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, CN, $-CF_3$, or $-OH$~~;

R_7 is selected from ~~$-(CH_2)_n$-COOH, $-(CH_2)_n$-N-(C_1-C_6 alkyl)$_2$, $-(CH_2)_n$-NH-(C_1-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl,~~ C_3-C_5 cycloalkyl, ~~C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6~~

~~alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl,~~ and phenyl,~~-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,~~ the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$,CO_2H, or -OH;

~~n is an integer from 0 to 3;~~

R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, ~~preferably C_1-C_6 alkyl,~~ C_1-C_{10} alkoxy, ~~preferably C_1-C_6 alkoxy,~~ -CHO, -CN, $-NO_2$, $-NH_2$, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or $-SO_2$-C_1-C_6 alkyl;

R_3 is selected from H, $-CF_3$, -COOH, C_1-C_6 ~~lower~~ alkyl, C_1-C_6 ~~lower~~ alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl-C_3-C_{10} cycloalkyl, -CHO, halogen, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, ~~preferably 0 to 2, more preferably 0 to 1,~~ Y is C_1-C_6 alkyl, C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl, morpholinyl, pyrrolidinyl, or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O~~, preferably S or O~~;

R_4 is selected from the group of C_1-C_6 ~~lower~~ alkyl, C_1-C_6 ~~lower~~ alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, ~~preferably 0 to 2, more preferably 0 to 1,~~ Y is C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2 or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O~~, preferably S or O; or~~

~~b) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:~~



~~wherein~~

~~D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;~~

~~B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2; or~~

~~c) a moiety of the formulae:~~





wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, $-OH$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH_2$, or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$, $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $-C(O)C(O)X$;
where X = O,N

M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

~~ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or~~

~~iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, indole, indoline, napthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;~~

n is an integer from 0 to 3;

R_5 is ~~selected from -COOH, -C(O)-COOH, $-(CH_2)_n$-C(O)-COOH, $-(CH_2)_n$-COOH, $-CH_2$-phenyl-C(O)-benzothiazole, $-(CH_2)_n$-CH=CH-COOH,~~




(CH2)n
OH
R8
R9
R10
NH
S
O
N
H
R11
(C1-C6 lower alkyl)
(C1-C6 lower haloalkyl)
n

~~n is an integer from 0 to 3;~~

R_8 is ~~selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,~~



~~, or~~

~~n is an integer from 0 to 3;~~

R_9 is ~~selected from H, halogen, -CF_3, -OH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$;~~

~~n is an integer from 0 to 3;~~

R_{10} is ~~selected from the group of H, halogen, -CF_3, -OH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$,~~





(C_1-C_6 lower alkyl), ~~or~~ (C_1-C_6 lower haloalkyl) ~~or~~



(C_1-C_6 lower alkyl);

~~n is an integer from 0 to 3;~~

~~R_{11} is selected from H, C_1-C_6 lower alkyl, -CF_3, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, or~~



~~with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,~~



~~n is an integer from 0 to 3~~;
or a pharmaceutically acceptable salt thereof.

2. (Canceled).

3. (Currently amended): A compound of Claim ~~2~~ 1 wherein R_3 is H ~~and R_1, R_2, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, n, X, L^2, M^2, Z, A, B, C, D, and Y are as defined in Claim 2~~, or a pharmaceutically acceptable salt thereof.

4. (Currently amended) A compound of Claim ~~2~~ 1 having the formula:



~~wherein R_1 is benzyloxy, optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, CN, $-CF_3$, or -OH; and R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, n, X, L^2, M^2, Z, A, B, C, D, and Y are as defined in Claim 2~~, or a pharmaceutically acceptable salt thereof.

5. (Currently amended): A compound of Claim 4 ~~2~~



wherein~~:~~

~~R_1 is selected from halogen, $-NH_2$, -O-phenyl, benzyl, -O-benzyl, -N-benzyl, -N-benzyl-O-phenyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH; or R_1 is or a moiety of the formulae:~~



~~R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-CF_3$, or -OH;~~

~~R_7 is selected from $-(CH_2)_n$-COOH, $-(CH_2)_n$-N-(C_1-C_6 alkyl)$_2$, $-(CH_2)_n$-NH-(C_1-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6 alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-CF_3$, or -OH;~~

~~n is an integer from 0 to 3;~~

R_3 is ~~selected from H, $-CF_3$, -COOH, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1$-C_6 alkyl-C_3-C_{10} cycloalkyl, -CHO, halogen, or a moiety of the formulae:~~







wherein n is independently selected in each appearance as an integer from 0 to 3, preferably 0 to 2, more preferably 0 to 1, Y is C_1-C_6 alkyl, C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl, morpholinyl, pyrrolidinyl, or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O, preferably S or O;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n$-C_3-C_6 cycloalkyl, $-(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, $-(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$, $-CH_2$-phenyl-C(O)-benzothiazole or a moiety of the formulae:





wherein n is independently selected in each appearance as an integer from 0 to 3, preferably 0 to 2, more preferably 0 to 1, Y is C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O, preferably S or O; or

b) a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



~~wherein~~

~~D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;~~

~~B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, or $-NO_2$; or~~

~~c) a moiety of the formulae:~~



~~wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, $-OH$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, or $-NO_2$; or~~

~~d) a moiety of the formula $-L^2-M^2$, wherein:~~

~~L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, -C(O)C(O)X;~~
~~where X = O,N~~

~~M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or~~

~~i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or~~

~~ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or~~

~~iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, indole, indoline, napthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;~~

~~R_5 is selected from -COOH, -C(O)-COOH, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $-CH_2$-phenyl-C(O)-benzothiazole,~~
~~$(CH_2)_n-CH=CH-COOH$,~~





~~n is an integer from 0 to 3;~~

~~R_8 is selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,~~



~~n is an integer from 0 to 3;~~

~~R_9 is selected from H, halogen, -CF_3, -OH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$;~~

~~n is an integer from 0 to 3;~~

~~R_{10} is selected from the group of H, halogen, -CF_3, -OH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$,~~



~~or~~



~~n is an integer from 0 to 3;~~

~~R_{11} is selected from H, C_1-C_6 lower alkyl, $-CF_3$, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, or~~



~~with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,~~



~~n is an integer from 0 to 3;~~

or a pharmaceutically acceptable salt thereof.

6-9. (Canceled).

10. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(phenethylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

11. (Original) A compound of Claim 1 which is 4-[(3-chloro-5-[(cyclopentylcarbonyl)amino]-2-{[(2-furylmethyl)sulfanyl]methyl}-1H-indol-1-yl)methyl]benzoic acid or a pharmaceutically acceptable salt thereof.

12. (Original) A compound of Claim 1 which is 4-[(3-chloro-5-[(cyclopentylcarbonyl)amino]-2-{[(4-hydroxy-6-phenyl-2-pyrimidinyl)sulfanyl]methyl}-1H-indol-1-yl)methyl]benzoic acid or a pharmaceutically acceptable salt thereof.

13. (Original) A compound of Claim 1 which is 4-{[3-chloro-5-[(cyclopentylcarbonyl)amino]-2-({[4-(2-thienyl)-2-pyrimidinyl]sulfanyl}methyl)-1H-indol-1-yl]methyl}benzoic acid or a pharmaceutically acceptable salt thereof.

14. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(2,4-dibromophenoxy)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

15. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(cyclopentylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

16. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(propylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

17. (Original) A compound of Claim 1 which is 4-({2-{[4-(tert-butyl)phenoxy]methyl}-3-chloro-5-[(cyclopentylcarbonyl)amino]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

18. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(2-quinolinylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

19. (Original) A compound of Claim 1 which is 4-[(3-chloro-5-[(cyclopentylcarbonyl)amino]-2-{[(cyclopropylmethyl)sulfanyl]methyl}-1H-indol-1-yl)methyl]benzoic acid or a pharmaceutically acceptable salt thereof.

20. (Canceled).

21. (Original) A compound of Claim 1 which is 4-({5-[(3-carboxypropanoyl)amino]-3-chloro-2-[(phenethylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

22. (Original) A compound of Claim 1 which is 4-[(5-[(3-carboxypropanoyl)amino]-3-chloro-2-{[(3-methylbenzyl)sulfanyl]methyl}-1H-indol-1-yl)methyl]benzoic acid or a pharmaceutically acceptable salt thereof.

23. (Original) A compound of Claim 1 which is 4-({2-({[4-(tert-butyl)benzyl]sulfanyl}methyl)-5-[(3-carboxypropanoyl)amino]-3-chloro-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

24-27. (Canceled).

28. (Original) A compound of Claim 1 which is 4-({5-{[(benzylamino)carbonyl]amino}-3-chloro-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

29-34. (Canceled).

35. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)amino]-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

36-37. (Canceled).

38. (Original) A compound of Claim 1 which is 4-({5-{[(benzyloxy)carbonyl]amino}-3-chloro-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

39. (Original) A compound of Claim 1 which is 4-({3-chloro-5-{[(cyclopentyloxy)carbonyl]amino}-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

40-43. (Canceled).

44. (Original) A compound of Claim 1 which is 4-({5-(benzylamino)-3-chloro-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

45. (Original) A compound of Claim 1 which is 4-({3-chloro-2-[(2-naphthylsulfanyl)methyl]-5-[(3-phenoxybenzyl)amino]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

46. (Original) A compound of Claim 1 which is 4-({3-chloro-5-[(cyclopentylcarbonyl)(methyl)amino]-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

47. (Original) A compound of Claim 1 which is 4-({5-[acetyl(benzyl)amino]-3-chloro-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

48-51. (Canceled).

52. (Original) A compound of Claim 1 which is 4-({3-chloro-2-[(2-naphthylsulfanyl)methyl]-5-[(3-phenylpropanoyl)amino]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

53-66. (Canceled).

67. (Original) A compound of Claim 1 which is 4-({3-benzoyl-5-(benzyloxy)-2-[(2-naphthylsulfanyl)methyl]-1H-indol-1-yl}methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

68-94. (Canceled).

95. (Currently amended): A method of inhibiting the phospholipase activity of an enzyme in a mammalian subject in need thereof comprising administering to said subject a therapeutically effective amount of a ~~pharmaceutical composition~~ compound of claim 1.

96. (Currently amended): A method of treating an inflammatory response in a mammalian subject in need thereof comprising administering to said subject a therapeutically effective amount of a ~~pharmaceutical composition~~ compound of Claim 1.

97. (Original): A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.